Progress of research on biomarkers in peritoneal dialysis effluent

doi:10.3877/cma.j.issn.2095-3216.2015.01.009

Abstract

Abstract:

Long-term peritoneal dialysis can lead to alterations in the function and morphology of peritoneal membrane. Peritoneal function evaluation mainly consists of clearance of both small molecule solute and liquid, being relatively simple. But morphology assessment relies on the peritoneal biopsy that is difficult to be clinically applied. How to evaluate peritoneal changes through accurate, convenient, and noninvasive ways has long been a focus. As the peritoneal tissue is immersed in the peritoneal fluid continuously, some substances may inevitably detached or be secreted, which are the unique and convenient specimens for detection in peritoneal dialysis patients. It will help to understand the peritoneal pathophysiological changes to collect peritoneal dialysis effluent in order to find and determine the potential substances. Therefore, this present paper has reviewed the candidate biomarkers emerging from peritoneal dialysis study as well as their prospect in clinical application..

Key words: Peritoneal dialysis effluent, Biomarkers, Mesothelial cells

Xueying Cao, Jianhui Zhou, Guangyan Cai, Xiangmei Chen. Progress of research on biomarkers in peritoneal dialysis effluent[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2015, 04(01): 43-48.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2015.01.009

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2015/V04/I01/43

Figures/Tables 1

References 65

[1]	Coester AM, Smit W, Struijk DG, et al. Peritoneal function in clinical practice: the importance of follow-up and its measurement in patients. Recommendations for patient information and measurement of peritoneal function [J]. NDT plus, 2009, 2(2): 104-110.
[2]	Krediet RT, Struijk DG. Peritoneal dialysis membrane evaluation in clinical practice [J]. Contrib Nephrol, 2012, 178: 232-237.
[3]	Sampimon DE, Coester AM, Struijk DG, et al. The time course of peritoneal transport parameters in peritoneal dialysis patients who develop encapsulating peritoneal sclerosis [J]. Nephrol Dial Transplant, 2011, 26(1): 291-298.
[4]	Mateijsen MA, van der Wal AC, Hendriks PM, et al. Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis [J]. Perit Dial Int, 1999, 19(6): 517-525.
[5]	Zweers MM, Splint LJ, Krediet RT, et al. Ultrastructure of basement membranes of peritoneal capillaries in a chronic peritoneal infusion model in the rat [J]. Nephrol Dial Transplant, 2001, 16(3): 651-654.
[6]	Williams JD, Craig KJ, Topley N, et al. Morphologic changes in the peritoneal membrane of patients with renal disease[J]. J Am Soc Nephrol, 2002, 13(2): 470-479.
[7]	Combet S, Miyata T, Moulin P, et al. Vascular proliferation and enhanced expression of endothelial nitric oxide synthase in human peritoneum exposed to long-term peritoneal dialysis [J]. J Am Soc Nephrol, 2000, 11(4): 717-728.
[8]	Cuccurullo M, Evangelista C, Vilasi A, et al. Proteomic analysis of peritoneal fluid of patients treated by peritoneal dialysis: effect of glucose concentration [J]. Nephrol Dial Transplant, 2011, 26(6): 1990-1999.
[9]	Raaijmakers R, Pluk W, Schroder CH, et al. Proteomic profiling and identification in peritoneal fluid of children treated by peritoneal dialysis [J]. Nephrol Dial Transplant, 2008, 23(7): 2402-2405.
[10]	Lin WT, Tsai CC, Chen CY, et al. Proteomic analysis of peritoneal dialysate fluid in patients with dialysis-related peritonitis [J]. Renal failure, 2008, 30(8): 772-777.
[11]	Wang HY, Tian YF, Chien CC, et al. Differential proteomic characterization between normal peritoneal fluid and diabetic peritoneal dialysate [J]. Nephrol Dial Transplant, 2010, 25(6): 1955-1963.
[12]	Sritippayawan S, Chiangjong W, Semangoen T, et al. Proteomic analysis of peritoneal dialysate fluid in patients with different types of peritoneal membranes [J]. J Proteome Res, 2007, 6(11): 4356-4362.
[13]	Sakurada T, Kojima S, Oishi D, et al. Prothrombin fragment 1 ＋ 2 (F1 ＋ 2) in effluent is a useful marker for peritoneal permeability in peritoneal dialysis patients using neutral dialysate [J]. Adv Perit Dial, 2011, 27: 2-5.
[14]	Goedde M, Sitter T, Schiffl H, et al. Coagulation- and fibrinolysis-related antigens in plasma and dialysate of CAPD patients [J]. Perit Dial Int, 1997, 17(2): 162-166.
[15]	de Boer AW, Levi M, Reddingius RE, et al. Intraperitoneal hypercoagulation and hypofibrinolysis is present in childhood peritonitis [J]. Pediatr Nephrol, 1999, 13(4): 284-287.
[16]	Lopes BD, Coester AM, Noordzij M, et al. Variability of effluent cancer antigen 125 and interleukin-6 determination in peritoneal dialysis patients [J]. Nephrol Dial Transplant, 2011, 26(11): 3739-3744.
[17]	Pecoits-Filho R, Araujo MR, Lindholm B, et al. Plasma and dialysate IL-6 and VEGF concentrations are associated with high peritoneal solute transport rate [J]. Nephrol Dial Transplant, 2002, 17(8)：1480-1486.
[18]	Rodrigues AS, Almeida M, Fonseca I, et al. Peritoneal fast transport in incident peritoneal dialysis patients is not consistently associated with systemic inflammation [J]. Nephrol Dial Transplant, 2006, 21(3): 763-769.
[19]	van Esch S, Zweers MM, Jansen MA, et al. Determinants of peritoneal solute transport rates in newly started nondiabetic peritoneal dialysis patients [J]. Perit Dial Int, 2004, 24(6): 554-561.
[20]	Williams JD, Topley N, Craig KJ, et al. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane [J]. Kidney Int, 2004, 66(1): 408-418.
[21]	Mizutani M, Ito Y, Mizuno M, et al. Connective tissue growth factor (CTGF/CCN2) is increased in peritoneal dialysis patients with high peritoneal solute transport rate [J]. Am J Physiol Renal Physiol, 2010, 298(3): F721-F733.
[22]	Margetts PJ, Kolb M, Galt T, et al. Gene transfer of transforming growth factor-beta1 to the rat peritoneum: effects on membrane function [J]. J Am Soc Nephrol, 2001, 12(10): 2029-2039.
[23]	Jones S, Holmes CJ, Krediet RT, et al. Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels [J]. Kidney Int, 2001, 59(4): 1529-1538.
[24]	Sampimon DE, Korte MR, Barreto DL, et al. Early diagnostic markers for encapsulating peritoneal sclerosis: a case-control study [J]. Perit Dial Int, 2010, 30(2): 163-169.
[25]	Ahmad S, North BV, Qureshi A, et al. CCL18 in peritoneal dialysis patients and encapsulating peritoneal sclerosis [J]. Eur J Clin Invest, 2010, 40(12): 1067-1073.
[26]	Szeto CC, Wong TY, Lai KB, et al. Dialysate hyaluronan concentration predicts survival but not peritoneal sclerosis in continuous ambulatory peritoneal dialysis [J]. Am J Kidney Dis, 2000, 36(3): 609-614.
[27]	Hirahara I, Inoue M, Umino T, et al. Matrix metalloproteinase levels in the drained dialysate reflect the peritoneal solute transport rate: a multicentre study in Japan [J]. Nephrol Dial Transplant, 2011, 26(5): 1695-1701.
[28]	Barreto DL, Coester AM, Struijk DG, et al. Can effluent matrix metalloproteinase 2 and plasminogen activator inhibitor 1 be used as biomarkers of peritoneal membrane alterations in peritoneal dialysis patients [J] ? Perit Dial Int, 2013, 33(5): 529-537.
[29]	Rippe B, Simonsen O, Heimburger O, et al. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products [J]. Kidney Int, 2001, 59(1): 348-357.
[30]	le PCY, Welten AG, Weijmer MC, et al. Initiating CAPD with a regimen low in glucose and glucose degradation products, with icodextrin and amino acids (NEPP) is safe and efficacious [J]. Perit Dial Int, 2005, 25(Suppl 3): S64-S68.
[31]	Ho-dac-Pannekeet MM, Hiralall JK, Struijk DG, et al. Longitudinal follow-up of CA125 in peritoneal effluent [J]. Kidney Int, 1997, 51(3): 888-893.
[32]	Lopes Barreto D, Coester AM, Noordzij M, et al. Variability of effluent cancer antigen 125 and interleukin-6 determination in peritoneal dialysis patients [J]. Nephrol Dial Transplant, 2011, 26(11): 3739-3744.
[33]	Szeto CC, Chow KM, Lam CW, et al. Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products--a 1-year randomized control trial [J]. Nephrol Dial Transplant, 2007, 22(2): 552-559.
[34]	Haas S, Schmitt CP, Arbeiter K, et al. Improved acidosis correction and recovery of mesothelial cell mass with neutral-pH bicarbonate dialysis solution among children undergoing automated peritoneal dialysis [J]. J Am Soc Nephrol, 2003, 14(10): 2632-2638.
[35]	Pecoits-Filho R, Carvalho MJ, Stenvinkel P, et al. Systemic and intraperitoneal interleukin-6 system during the first year of peritoneal dialysis[J]. Perit Dial Int, 2006, 26(1): 53-63.
[36]	Pecoits-Filho R, Barany P, Lindholm B, et al. Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment [J]. Nephrol Dial Transplant, 2002, 17(9): 1684-1688.
[37]	Zemel D, ten BRJ, Struijk DG, et al. Interleukin-6 in CAPD patients without peritonitis: relationship to the intrinsic permeability of the peritoneal membrane [J]. Clin Nephrol, 1992, 37(2): 97-103.
[38]	Rodrigues AS, Martins M, Korevaar JC, et al. Evaluation of peritoneal transport and membrane status in peritoneal dialysis: focus on incident fast transporters [J]. Am J Nephrol, 2007, 27(1): 84-91.
[39]	Sawai A, Ito Y, Mizuno M, et al. Peritoneal macrophage infiltration is correlated with baseline peritoneal solute transport rate in peritoneal dialysis patients [J]. Nephrol Dial Transplant, 2011, 26(7): 2322-2332.
[40]	Oh KH, Moon JY, Oh J, et al. Baseline peritoneal solute transport rate is not associated with markers of systemic inflammation or comorbidity in incident Korean peritoneal dialysis patients [J]. Nephrol Dial Transplant, 2008, 23(7): 2356-2364.
[41]	Johnson DW, Hawley CM, McDonald SP, et al. Superior survival of high transporters treated with automated versus continuous ambulatory peritoneal dialysis [J]. Nephrol Dial Transplant, 2010, 25(6): 1973-1979.
[42]	Gillerot G, Goffin E, Michel C, et al. Genetic and clinical factors influence the baseline permeability of the peritoneal membrane [J]. Kidney Int, 2005, 67(6): 2477-2487.
[43]	Hwang YH, Son MJ, Yang J, et al. Effects of interleukin-6 T15A single nucleotide polymorphism on baseline peritoneal solute transport rate in incident peritoneal dialysis patients [J]. Perit Dial Int, 2009, 29(1): 81-88.
[44]	Lee YT, Tsai YC, Yang YK, et al. Association between interleukin-10 gene polymorphism -592 (A/C) and peritoneal transport in patients undergoing peritoneal dialysis [J]. Nephrology, 2011, 16(7): 663-671.
[45]	Zemel D, Imholz AL, de Waart DR, et al. Appearance of tumor necrosis factor-alpha and soluble TNF-receptors I and II in peritoneal effluent of CAPD [J]. Kidney Int, 1994, 46(5): 1422-1430.
[46]	Zweers MM, de Waart DR, Smit W, et al. Growth factors VEGF and TGF-beta1 in peritoneal dialysis [J]. J Lab Clin Med, 1999, 134(2): 124-132.
[47]	Dvorak HF, Brown LF, Detmar M, et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis [J]. Am J Pathol, 1995, 146(5): 1029-1039.
[48]	Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders [J]. N Engl J Med, 1994, 331(22): 1480-1487.
[49]	Shimo T, Nakanishi T, Nishida T, et al. Connective tissue growth factor induces the proliferation, migration, and tube formation of vascular endothelial cells in vitro, and angiogenesis in vivo [J]. J Biochem, 1999, 126(1): 137-145.
[50]	Gregory PA, Bert AG, Paterson EL, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1 [J]. Nat Cell Biol, 2008, 10(5): 593-601.
[51]	Korpal M, Lee ES, Hu G, et al. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2 [J]. J Biol Chem, 2008, 283(22): 14910-14914.
[52]	Chen J, Kam-Tao P, Kwan BC, et al. Relation between microRNA expression in peritoneal dialysis effluent and peritoneal transport characteristics [J]. Dis Markers, 2012, 33(1)：35-42.
[53]	Sitter T, Spannagl M, Schiffl H, et al. Imbalance between intraperitoneal coagulation and fibrinolysis during peritonitis of CAPD patients: the role of mesothelial cells [J]. Nephrol Dial Transplant, 1995, 10(5): 677-683.
[54]	Dobbie JW, Lloyd JK, Gall CA. Categorization of ultrastructural changes in peritoneal mesothelium, stroma and blood vessels in uremia and CAPD patients [J]. Adv Perit Dial, 1990, 6：3-12.
[55]	Lai KN, Szeto CC, Lai KB, et al. Increased production of hyaluronan by peritoneal cells and its significance in patients on CAPD [J]. Am J Kidney Dis, 1999, 33(2): 318-324.
[56]	Ho-dac-Pannekeet MM, Hiralall JK, Struijk DG, et al. Markers of peritoneal mesothelial cells during treatment with peritoneal dialysis [J]. Adv Perit Dial, 1997, 13: 17-22.
[57]	Graff J, Joffe P, Fugleberg S, et al. Collagen markers in peritoneal dialysis patients [J]. Adv Perit Dial, 1995, 11: 24-27.
[58]	Digenis GE, Dombros NV, Balaskas EV, et al. Procollagen-I and collagen-I in the serum and dialysate of CAPD patients: changes over time [J]. Perit Dial Int, 1995, 15(8): 371-374.
[59]	Dawson S, Henney A. The status of PAI-1 as a risk factor for arterial and thrombotic disease: a review[J]. Atherosclerosis, 1992, 95(2-3)：105-117.
[60]	Holmdahl L, Falkenberg M, Ivarsson ML, et al. Plasminogen activators and inhibitors in peritoneal tissue [J]. APMIS, 1997, 105(1): 25-30.
[61]	Marshall BC, Santana A, Xu QP, et al. Metalloproteinases and tissue inhibitor of metalloproteinases in mesothelial cells. Cellular differentiation influences expression [J]. J Clin Invest, 1993, 91(4): 1792-1799.
[62]	Margetts PJ, Bonniaud P, Liu L, et al. Transient overexpression of TGF-{beta}1 induces epithelial mesenchymal transition in the rodent peritoneum [J]. J Am Soc Nephrol, 2005, 16(2): 425-436.
[63]	Khasigov PZ, Podobed OV, Ktzoeva SA, et al. Matrix metalloproteinases of normal human tissues [J]. Biochemistry, 2001, 66(2): 130-140.
[64]	Hirahara I, Inoue M, Okuda K, et al. The potential of matrix metalloproteinase-2 as a marker of peritoneal injury, increased solute transport, or progression to encapsulating peritoneal sclerosis during peritoneal dialysis--a multicentre study in Japan [J]. Nephrol Dial Transplant, 2007, 22(2): 560-567.
[65]	Hirata H, Miyamoto H, Shimokawa K, et al. Novel diagnostic method of peritoneal injury using dual macromolecular markers [J]. Biol Pharm Bull, 2014, 37(2): 262-267.

滤出液标志物	是否腹膜产生	参与病理
纤维蛋白单体^[13]	＋	凝血和纤容
纤溶酶原激活物抑制剂-1^[14,15]	＋	纤维化
I白介素-6^{[16,17,18,19]}	＋	促炎/抗炎、诱导合成肝脏急性期蛋白质
肿瘤坏死因子-α^[20]	－	血管生成、纤维化、急性炎症
E-选择素	＋/－	细胞粘附
结缔组织生长因子^[21]	＋	血管生成、细胞粘附和纤维化
转化生长因子-β^[22,23]	＋	血管生成、纤维化和刺激细胞外基质形成
血管内皮生长因子^[24]	＋	血管新生和增加血管通透性
CC趋化因子配体18^[25]	－	纤维化
透明质酸^[26]	＋	结缔组织含量
基质金属蛋白酶-2^[27,28]	＋	上皮间质转化、纤维化、组织重塑
前胶原肽^[20,29]	＋	纤维化
癌抗原125^{[16,20,23,29,30]}	＋	间皮细胞量

滤出液标志物	是否腹膜产生	参与病理
纤维蛋白单体^[13]	＋	凝血和纤容
纤溶酶原激活物抑制剂-1^[14,15]	＋	纤维化
I白介素-6^{[16,17,18,19]}	＋	促炎/抗炎、诱导合成肝脏急性期蛋白质
肿瘤坏死因子-α^[20]	－	血管生成、纤维化、急性炎症
E-选择素	＋/－	细胞粘附
结缔组织生长因子^[21]	＋	血管生成、细胞粘附和纤维化
转化生长因子-β^[22,23]	＋	血管生成、纤维化和刺激细胞外基质形成
血管内皮生长因子^[24]	＋	血管新生和增加血管通透性
CC趋化因子配体18^[25]	－	纤维化
透明质酸^[26]	＋	结缔组织含量
基质金属蛋白酶-2^[27,28]	＋	上皮间质转化、纤维化、组织重塑
前胶原肽^[20,29]	＋	纤维化
癌抗原125^{[16,20,23,29,30]}	＋	间皮细胞量

Please choose a citation manager

Content to export